27 August 2018 : Clinical Research
MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2)Na Li1BC, Mei Han1AB, Ning Zhou1BC, Yong Tang1DE, Xu-Shan Tang1DE*
Med Sci Monit 2018; 24: CLR5960-5972
BACKGROUND: In recent years, the incidence of gastric cancer (GC) presents is increasing and plagues people worldwide. Emerging evidence shows that microRNAs (miRs) may be involved in the pathogenesis of GC. Thus, this paper aims to explore the mediatory role of miR-495 in GC chemosensitivity, and the mechanism by which it affected the biological behaviors of GC cell via the mTOR signaling pathway.
MATERIAL AND METHODS: After GC and paracancerous tissue collection, the positive rate of ERBB2 and mTOR was evaluated by immunohistochemistry. Subsequently, the expression of miR-495, ERBB2 and mTOR was determined by RT-qPCR and western blot analysis. Next, the targeting relationship between miR-495 and ERBB2 was confirmed by dual-luciferase reporter gene assay. In addition, chemosensitivity and proliferation were detected by MTT assay, and apoptosis by flow cytometry.
RESULTS: We firstly observed that higher positive rate of ERBB2 and mTOR as well as decreased expression of miR-495 were found in GC tissues. Additionally, ERBB2 is the target gene of miR-495. Furthermore, it was determined that overexpressed miR-495 or silencing ERBB2 enhanced GC cells chemosensitivity and apoptosis, but inhibited GC cell proliferation. Besides, we found that the effect of miR-495 inhibition was lost when ERBB2 was suppressed.
CONCLUSIONS: The key findings of our study demonstrate that the miR-495 exerts promoting effects on GC chemosensitivity via the inactivation of mTOR signaling pathway by suppressing ERBB2. The study provides reliable reference for the application of miR-495 as a novel potential target in the chemotherapy of GC.
Keywords: Gastroenterology, Stomach Diseases
01 July 2022 : EditorialEditorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2
Med Sci Monit 2022; 28:e937676
27 June 2022 : Clinical ResearchShoulder Injury Related to Vaccine Administration (SIRVA) in 16 Patients Following COVID-19 Vaccination Who...
Med Sci Monit In Press; DOI: 10.12659/MSM.937430
04 June 2022 : Clinical ResearchScreening for SARS-CoV-2 Infection in Students at the Medical University of Warsaw, Poland Between November...
Med Sci Monit 2022; 28:e936962
30 May 2022 : Clinical ResearchEffects of Wearing Face Masks on Exercise Capacity and Ventilatory Anaerobic Threshold in Healthy Subjects ...
Med Sci Monit 2022; 28:e936069
05 Jul 2022 : Clinical ResearchAttention-Deficit/Hyperactivity Disorder (ADHD) and Time Perception in Adults: Do Adults with Different ADH...
Med Sci Monit In Press; DOI: 10.12659/MSM.936849
01 Jul 2022 : Clinical ResearchDoes Early-Period Patient Dissatisfaction Turn Into Satisfaction Over Time After Total Knee Replacement?
Med Sci Monit In Press; DOI: 10.12659/MSM.936792
30 Jun 2022 : Laboratory ResearchBcl-2 19-kDa Interacting Protein 3 (BNIP3)-Mediated Mitophagy Attenuates Intermittent Hypoxia-Induced Human...
Med Sci Monit In Press; DOI: 10.12659/MSM.936760
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788